Objective: Aortic valve replacement (AVR) can be performed either through full median sternotomy (FS) or upper mini-sternotomy (MS). The Mini-Stern trial aimed to establish whether MS leads to quicker postoperative recovery and shorter hospital stay after first-time isolated AVR.
Results: In this RCT, 222 patients were recruited and randomized (n ¼ 118 in the MS group; n ¼ 104 in the FS group). Compared with the FS group, the MS group had a longer hospital length of stay (mean, 9.5 days vs 8.6 days) and took longer to achieve fitness for discharge home (mean, 8.5 days vs 7.5 days). Adjusting for valve type, sex, and surgeon, hazard ratios (HRs) from Cox models did not show a statistically significant effect of MS (relative to FS) on either hospital stay (HR, 0.874; 95% confidence interval [CI] , 0.668-1.143; P ¼ .3246) or time to fitness for discharge (HR, 0.907; 95% CI, 0.688-1.197; P value ¼ .4914). During a mean follow-up of 760 days (745 days for the MS group and 777 days for the FS group), 12 patients (10%) in the MS group and 7 patients (7%) in the FS group died (HR, 1.871; 95% CI, 0.723-4.844; P ¼ .1966). Average extra cost for MS was £1714 during the first 12 months after AVR. Duration of hospital stay after aortic valve replacement: full median sternotomy versus mini-sternotomy.
Central Message
In the United Kingdom's National Health Service, compared with a conventional median sternotomy approach for surgical aortic valve replacement, mini-sternotomy did not hasten recovery or hospital discharge and was not cost-effective.
Perspective
Minimal access surgery is appealing for its perceived advantages, including better patient recovery, satisfaction, and cost-effectiveness. This randomized controlled trial conducted within the United Kingdom's National Health Service setting did not demonstrate quicker patient recovery or cost-effectiveness associated with mini-sternotomy compared with a full median sternotomy approach. These findings are relevant to physicians, patients, and health care funders.
Aortic valve replacement (AVR) is the second most frequent cardiac surgery in the United Kingdom, 1 which has an ever-increasing proportion of older patients. 1, 2 Minimal access AVR (mAVR) might shorten the hospital stay and the postoperative recovery period and could be beneficial if offered safely and cost-effectively.
Currently, most AVRs are performed safely through full median sternotomy (FS). [2] [3] [4] [5] [6] However, mAVR may be associated with less postoperative pain and blood loss, fewer pulmonary and wound complications, and a shorter hospital stay. 2 The most common mAVR technique involves a mini-sternotomy (MS), which could potentially hasten postoperative recovery, shorten hospital stay and improve patient satisfaction. [2] [3] [4] [5] [6] [7] [8] [9] [10] Most previous studies comparing MS and FS for AVR were nonrandomized. Although systematic reviews with meta-analyses 11, 12 have been conducted, inadequate statistical power and heterogeneity of studies calls for prospective, randomized controlled trials (RCTs) to assess the benefits and risks of mAVR. Published evidence on cost-effectiveness comparing MS and FS is sparse and weak. A recent review comparing the cost-effectiveness of FS and MS called for a well-designed RCT to evaluate the cost-effectiveness of mAVR up to at least 1 year after surgery. 13 A recent propensity-matched study from United Kingdom national data concluded that mAVR is safe and associated with shorter postoperative hospital stay. 14 The authors concluded that although general clinical equipoise exists between FS and MS, a well-constructed and adequately powered RCT is essential before widespread adoption of MS. That retrospective study did not analyze the cost-effectiveness of either surgical approach, however. The Mini-Stern trial assessed whether MS is superior to FS in shortening postoperative recovery time and improving patient outcomes without compromising patient safety. It also assessed the cost-effectiveness of MS from the perspective of the United Kingdom's National Health Service (NHS) as a health care provider.
MATERIALS AND METHODS
Mini-Stern was a 2-center, pragmatic, open-label RCT conducted in the United Kingdom. Patients were randomized (1:1) to AVR by either MS or FS.
Sample Size
In 4 published RCTs 5,6,9,10 and 2 cohort studies, 7, 8 a 20% reduction in median length of hospital stay from 11.7 to 9.36 days was considered clinically significant. Based on an internal audit of 252 first-time elective AVRs performed at Papworth Hospital in 2007 to 2008 (mean hospital length of stay, 11.7 [6.2] days), to detect this change with 80% power and 2-sided significance of 5%, 110 patients per group were required. Because randomization was performed on the day of surgery after induction of anesthesia and introduction of the transesophageal echocardiography (TOE) probe, no subjects dropped out between randomization and surgery, thereby achieving the total trial recruitment target of 220 patients.
Recruitment
Adult patients undergoing first-time isolated AVR were included. Exclusion criteria included emergency AVR, left ventricular ejection fraction 30%, chest wall deformities, severe chronic obstructive pulmonary disease (forced expiratory volume in 1 second or transfer factor of the lung for carbon monoxide <40% of predicted), body mass index >35 kg/m 2 , concomitant cardiac surgery, redo surgery, and inability to perform TOE. Details of patient enrolment are given in the online protocol.
Randomization
Randomization (1:1) used random permuted blocks of variable lengths (6 or 8) , stratified by surgeon and valve prosthesis (bioprosthetic or mechanical). Random allocations were pregenerated, held in secure files by the Papworth Trials Unit. During early days of the trial, TOE probe could not be passed in 4 patients due to technical reasons. These patients underwent the allocated procedure and were included in the trial. Subsequently, the Trial Steering Committee determined that under such circumstances, MS would be unsafe, and patients should be excluded from the trial to FS. Because eligibility for MS required TOE, to avoid postrandomization dropout, group allocation for the study subjects was retrieved via telephone by theatre staff soon after induction of anesthesia and introduction of the TOE probe. Owing to the nature of the interventions, this trial could not be blinded.
affect health-related quality of life (HRQoL); and (2) the interval between surgery and the patient being medically fit for discharge (in days). To reduce investigator bias, standard discharge criteria were followed to determine the day of fitness for discharge. This endpoint was chosen to address exogenous effects (eg, social factors, lack of transport, nonavailability of space in nursing homes) that commonly delay hospital discharge in the United Kingdom.
Secondary endpoints. Clinical secondary endpoints included duration of surgery, total theatre time, aortic cross-clamp and cardiopulmonary bypass (CPB) times, blood loss in the first 12 hours after surgery, transfusion of blood and clotting products in the first 48 hours (the blood transfusion trigger was a hemoglobin level<80 g/L), frequency of reintubation, time to initial extubation, mediastinal drain removal and first independent mobilization, daily pain scores at rest and on deep breathing (over the first 10 days or until hospital discharge) on a scale of 0 to 10, left ventricular ejection fraction, severity of paraprosthetic regurgitation at hospital discharge and at 6 months, and time to all-cause death. Definitions of adverse events and details of their reporting are provided in the online protocol. To exclude bias, clinical outcome data were collected by a research team not involved in routine care of the subjects, following standardized protocols.
Nonclinical secondary endpoints included HRQoL and health care resource use.
HRQoL. Patients completed the EQ-5D-3L 15 and Short Form Health Survey (SF-36) 16, 17 questionnaires at baseline and at 6 weeks, 6 months, and 12 months postsurgery. The EQ-5D-3L was repeated on the fourth postoperative day and at discharge.
Health care resource use. Patient-specific resource use data collected from hospital records and patient interviews during the primary admission included phases of care (operative surgery, critical care, and postsurgical ward care) and medication administration. Postdischarge resource use included attending wound clinics, community nurse visits, physiotherapy sessions, occupational therapy services, medical tests, cost of analgesics and other drugs, and further hospitalization within the first year after AVR.
Surgical Details
All participating surgeons were consultants experienced in performing AVR by both FS and MS. They followed the operative surgical protocol as described below. Video 1 shows the MS approach and is available in the online version of this article.
MS approach. With the patient anesthetized in accordance with standard protocol, skin was incised from halfway between the suprasternal notch and the sternal angle to the level of the fourth intercostal space, approximately 8 cm. The manubrium was divided in the midline from the suprasternal notch inferiorly and then into the right fourth intercostal space. The thymus was divided and the pericardium was opened, exposing the ascending aorta, aortic root, and right atrial appendage. A 300 U/kg loading dose of unfractionated heparin followed by boluses of 5000 U was administered to achieve activated clotting time >450 seconds. The aorta was cannulated using a wired flexible aortic cannula. The right atrial appendage was cannulated using a flat venous cannula, and CPB was initiated. The ascending aorta was cross-clamped and intermittent, antegrade, cold blood cardioplegia administered. The aorta was then incised open in an oblique or transverse fashion, the diseased valve was excised, and the annulus was decalcified. A suitably sized aortic valve prosthesis was inserted using either horizontal mattress 2-0 Ethibond sutures or semi-continuous 2-0 Prolene sutures. Surgeons adopted either of these suture techniques and adhered to the same technique irrespective of the type of valve prosthesis or the surgical approach. The aortotomy was then closed, the heart was deaired, right atrial and ventricular epicardial pacing wires were inserted, and the patient was weaned off CPB. Once satisfactory functioning of the aortic valve prosthesis was confirmed by TOE, heparin was reversed with protamine (1 mg/100 U of heparin). Chest drains were inserted into the anterior mediastinum, posterior pericardial space, and pleural space as necessary. Sternal wires were inserted, and the incision was closed in layers. Conversion to FS was performed to ensure patient safety if access proved difficult or if intraoperative complications occurred.
FS approach. Anesthesia and positioning of patients was the same as for the MS approach. The skin incision was made between the suprasternal notch and the xiphoid process and sternum divided in the midline from the suprasternal notch to the xiphoid process. A 2-stage venous cannula was used for atrial cannulation. The remaining steps were similar to those for the MS approach.
Statistical Analysis
Analyses of primary and secondary endpoints used intention-to-treat and included all randomized patients. Unless stated otherwise, statistical models included treatment (MS vs FS), valve (mechanical vs bioprosthetic), and sex as fixed effects and surgeons as random effects. Hypothesis testing was 2-sided at a 5% significance level, with no adjustments for multiple testing. All confidence intervals (CIs) were estimated at the 95% confidence level.
Distributions of time-to-event endpoints were compared between study groups using Kaplan-Meier curves and log-rank tests (stratified by sex, valve, and surgeon). Hazard ratios (HRs) for MS relative to FS were estimated from a Cox model. The null hypothesis of no treatment effect (HR ¼ 1) was tested. Patients who were lost to follow-up, withdrew, or died before the event were censored at the latest time they were known to be event-free. Models were checked by plotting Schoenfeld and deviance residuals. For primary endpoints, Cox models were refitted using the per-protocol population and used in sensitivity analyses (Appendix E1, Table E4 ).
The need for reintubation and other dichotomous endpoints were compared between groups by estimating an MS/FS odds ratio (OR) via logistic regression. EQ-5D, SF-36, and pain scores were modeled using repeated-measures linear regression. When possible, random intercepts and random time coefficients for patients were included. For EQ-5D and SF-36, fixed effects for baseline scores were included. Models were fitted using complete cases, then refitted with multiple imputation of missing scores via chained equations.
Serious adverse events (SAEs) were analyzed in the safety population according to intervention received. Patients randomized to MS who crossed over to FS before surgery were considered to have received FS; those who crossed over after the initiation of MS were considered to have received MS. Rates of SAEs were explored using Poisson regression with a random patient effect.
CONSORT guidelines (Online Data Supplement and Figure E1 ) 18 were followed. Analyses were performed in SAS version 9.4 (SAS Institute, Cary, NC). No interim analyses were conducted, but reports were presented annually to the Data Monitoring and Ethics Committee. 
Economic Analysis
Unit costs were obtained from nationally published sources in the United Kingdom [19] [20] [21] [22] or from the Finance Department of Papworth Hospital when the former did not provide the required information. The total cost per patient was calculated by summing resource use items multiplied by unit costs across the in-patient stay and the 12-month postoperative follow-up period (Appendix E1, Table E22 ). Health state utilities from the EQ-5D-3L and SF-36, based on United Kingdom value sets, 15, 23 were used to generate quality-adjusted life years (QALYs) using the area under the curve method and assigning a value of 0 from the date of death. Missing values were imputed using chained predictive mean matching, stratified by treatment and conditional on age, sex, and baseline EQ-5D-3L data.
Differences in mean costs and QALYs were estimated using seemingly unrelated regression, controlling for age, sex, valve type, baseline EQ-5D-3L, and treatment to accommodate skewness. 24 Uncertainty in cost-effectiveness was estimated by drawing 1000 bootstrapped samples and conducting a probabilistic sensitivity analysis. Results are presented as incremental net monetary benefit at various thresholds of willingness to pay per QALY, cost-effectiveness planes, and cost-effectiveness acceptability curves. Deterministic sensitivity analyses explored the effects of using complete cases only, SF6D-based QALY estimates, and the procedure inpatient admission only and excluding patients who died and additional equipment costs (Appendix E1, Table E26 ).
RESULTS
A total of 1024 patients were screened between January 28, 2010, and April 13, 2015, of whom 222 were recruited and randomized to the MS (n ¼ 118) or FS (n ¼ 104) group. The 1-year follow-up was completed on May 23, 2016.
Study groups were similar at baseline except for a nonsignificant sex imbalance (Table 1) . In this trial, MS was not completed in 14 of 118 patients randomized to MS (12%). Of these patients, 6 (5%) had a conversion from MS to FS owing to reasons listed in Figure 1 . The remaining 8 patients underwent FS after randomization to MS but without an initial MS incision, because MS was considered unsafe or impractical. Thus, the true rate of intraoperative conversion of MS to FS was 5%. Four patients (2%) were censored before discharge, 1 patient who withdrew before surgery (FS group) and 3 patients who died (all randomized to and received MS) ( Table 2 ). Another 13 patients (6%) were censored before fitness for discharge, including 6 discharged to an acute hospital (3 in each group) and 7 discharged to long-term care or rehabilitation (3 in the FS group and 4 in the MS group).
The mean time to hospital discharge was longer in the MS group than in the FS group (9.5 days vs 8.6 days), as was mean time to fitness for discharge (8.5 days vs 7.5 days). The distributions of these endpoints were similar in the 2 groups, however ( Figure 2 and Table 2 ). The difference was not statistically significant in primary analyses using Cox models (Figure 3 ), log-rank tests (Table 2) , or sensitivity analyses (Table E4 ). The gamma-distributed frailty term in the Cox models was estimated to have a variance of 0.006675 for time to fitness and of 0.000100 for time to discharge, suggesting that surgeon heterogeneity was negligible.
The time to drain removal (including drains inserted/ retained to treat complications) was longer for the MS group, but times to extubation and independent mobilization did not differ significantly between the groups (Table 2 and Figure 3) , nor did the number of patients reintubated (6 in the MS group vs 5 in the FS group; OR, 1.039; 95% CI, 0.306-3.531; P ¼ .9512). Statistically significant HRs indicated longer duration of operative, CPB, cross-clamp, and theatre times for the MS group ( Figure 3) . No significant between-group differences were seen in blood loss (Table E3 ) or in the number of patients requiring transfusion of blood (50 in the MS group vs 51 in the FS group; OR, 0.797; 95% CI, 0.453-1.402; P ¼ .4310) or clotting products (11 in the MS group vs 4 in the FS group; OR, 2.616; 95% CI, 0.801-8.541; P ¼ .1112).
Regression models for pain at rest, EQ-5D utilities, and SF-36 domain scores (Tables E6-E8 ) estimated greater rates of improvement over time in MS patients for 3 SF-36 domains (social functioning, vitality, and role physical). After multiple imputation, the difference was only significant for the role physical domain (Table E9) . Pain on deep breathing was not analyzed, because only less than one-half of the data were collected owing to poor patient compliance.
Nine patients (4%) died within 1 year of surgery, including 7 (6%) in the MS group and 2 (2%) in the FS group. Five deaths were possibly related to treatment (4 in the MS group and 1 in the FS group), and none was likely or definitely related (Table E15) Economic analyses are summarized in Table 3 and the cost-effectiveness planes depicting cost-effectiveness between MS and FS are shown in Figure 4 . There was additional cost for MS relative to FS (£1714 per patient; P ¼ .0765) in the first year following surgery. Patients in QALY, Quality-adjusted life-year; SD, standard deviation; FS, full median sternotomy; MS, mini-sternotomy; ITU, intensive therapy unit; SE, standard error; ICER, incremental cost-effectiveness ratio; NMB, net monetary benefit; WTP, willingness to pay. *Incremental costs and effects estimated using SUR, adjusting for baseline differences.
the MS group had (nonsignificant) better EQ-5D-based QALYs (0.03 per patient; P ¼ .1509). The incremental cost per QALY gained was £61,379, but after adjusting for baseline characteristics, MS had higher costs and lower QALYs (ie, was dominated). In deterministic and probabilistic sensitivity analyses, MS was either dominated or had a very large cost per QALY, except for the complete case analysis (Tables E11 and E12 ).
DISCUSSION
The NHS is a free-for-patient at point-of-delivery health care system. Apart from good recovery, hospital discharge of a significant proportion of elderly patients depends on the timely availability of social care services in the community. The Mini-Stern trial is the first reported RCT comparing FS and MS for isolated AVR performed in a cohort of NHS patients.
In this prospective, pragmatic, open-label RCT, MS did not reduce the total duration of hospital stay after AVR. Because hospital discharge is sometimes delayed due to social factors, we included the time to fitness for discharge as a second primary endpoint. This was also not reduced by MS. These endpoints were recorded by physiotherapists based on a common discharge protocol with specific clinical milestones to achieve, thereby excluding physician-induced bias.
In this study, operation, total theatre, aortic cross-clamp, and CPB times were significantly prolonged with MS. This Cost-effectiveness planes. The proportion of points below each threshold gives the probability that MS is more cost-effective than FS. This probability is 3.7% for willingness to pay £20,000 per QALY and 5.1% for willingness to pay £30,000 per QALY. MS, Ministernotomy; FS, full median sternotomy; QALY, quality-adjusted life-year.
was expected, because in general, minimal access valve operations take longer. 5, 9 This would be justifiable if MS was associated with faster recovery, shorter postoperative stay, reduced cost of treatment, or, most importantly, a significant reduction in adverse events and hence superior patient safety. In this RCT, MS did not achieve these benefits, and thus we feel that the prolonged operation, total theatre, cross-clamp, and CPB times do not justify performing AVR through MS.
Two previous meta-analyses 11, 12 concluded that mAVR approaches are superior in certain aspects of postoperative recovery. However, both included studies on a mini-thoracotomy approach for AVR, and thus any inferences drawn cannot be extrapolated to MS. A retrospective propensity-matched analysis of data from a United Kingdom national database concluded that MS is safe and comparable to conventional AVR. 14 The authors found that MS resulted in a shorter postoperative hospital stay, in disagreement with our findings. However, a propensity-matched study can suffer from selection bias if its matching algorithm produces treatment groups that are unbalanced in some unobserved characteristics. A recent retrospective study demonstrated the safety of right thoracotomy minimally invasive isolated and concomitant AVR in patients of all age groups. 25 Because randomization balances study groups in known and unknown characteristics, results of the Mini-Stern trial should be more reliable than the findings of nonrandomized studies.
Previous studies investigating cost-effectiveness provided unclear conclusions. A report analyzing registry data from patients who underwent isolated primary AVR 26 reported lower hospital costs with AVR performed through a right anterior thoracotomy compared with sternotomy-based approaches, with no significant differences in outcomes. The main reasons for the lower costs were earlier hospital discharge and reduced use of blood products. Ghanta et al 27 noted that exclusion of rehabilitation costs could alter this finding. A review by Glauber et al, 13 based on uncontrolled studies, noted that the higher cost of instruments and devices in mAVR could be offset by economic advantage gained by shorter hospital stays and lower complication rates. The Mini-Stern trial assessed cost-effectiveness using a range of sensitivity analyses, but only the complete case analysis showed MS to be cost-effective, suggesting lower costs but slightly worse outcomes with MS. However, this analysis used a potentially unrepresentative sample of just 90 patients, and was restricted to the first year following operation, with no long-term analysis beyond 1 year.
This RCT is robust with many merits, including on-table randomization, comprehensive and independent outcome assessment without physician bias, longer-term clinical assessment, HRQoL analysis, and economic analysis. There are some limitations, however. Although we report on secondary endpoints, this trial was powered to address only the primary endpoint. A total of 14 patients (12%) allocated to MS received FS, another possible limitation. However, only 6 patients (5%) had true conversion after an attempted MS, whereas 8 patients (6.7%) went on to FS for safety reasons. Although this RCT was conducted in only 2 centers, thereby limiting generalizability, recruitment by 8 surgeons improved the generalizability. A total of 1024 patients were screened to recruit 222 patients (21.7%). Although this suggests potential selection bias, only 125 eligible patients (12.2%) failed recruitment, whereas the remaining 667 (65.1%) did not meet the inclusion criteria. Blinding was not practical, because sternotomy dressings were usually changed at 48 hours after surgery and patients became aware of the approach, which might have caused bias in self-reported outcomes. Missing ''pain at rest'' data were unlikely to be missing at random, and thus imputation might not have addressed all potential biases. Despite having 2 primary outcomes, we did not adjust for multiple testing; however, because neither showed a significant between-group difference, this would not have affected our conclusions.
CONCLUSIONS
In this study, MS for AVR was not associated with quicker recovery or earlier hospital discharge. MS resulted in longer operations, increased costs, and resulted in more SAEs than FS. Overall, this pragmatic RCT did not provide evidence that MS results in better clinical or quality of life outcomes, or that MS is cost-effective compared with FS in the first year after AVR.
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APPENDIX E1. ECONOMIC EVALUATION
This trial collected data on resource and health service use for each patient during their in-patient stay through to the end of follow-up at 1 year. The economic analysis compared the costs and quality of life impacts of full median sternotomy (FS) and mini-sternotomy (MS) and assessed the cost-effectiveness of MS as an alternative to FS.
The Methods section first presents the unit costs, resource use data and the methods used to aggregate resource use and utility data at a patient level. E1 The methods used to document and impute missing data follow. E2 The last part describes the construction of incremental cost-effectiveness ratios and representation of uncertainty.
Results are presented first for raw data (with and without imputation) for costs and quality-adjusted life-years (QALYs) separately, followed by estimations of costs and QALYs that account for baseline differences. The final section provides results of probabilistic and deterministic sensitivity analyses.
METHODS Unit Costs
All resource use data collected formed part of the patient-specific case-report form. Trained research nurses extracted data for inpatient stays from individual patient records. Face-to-face interviews with patients by research nurses provided data for quality of life as well as health service use during follow-up.
Multiplying the unit costs by each unit of resource use and summing these resource costs across each patient's 12-month follow-up from the date of operation enabled aggregation of total cost per patient. Table E16 provides the unit costs used, with source of data. Where possible, national estimates of unit prices were used (eg, Personal Social Services Research Unit, E3 National Health Service E4 ), to increase generalizability. All resources were used once by patients (eg, a general practitioner visit or specific test), with the exception of 2 capital items used during surgery; the horizontal saw and defibrillator handles, both acquired for MS. These costs were apportioned, using clinical opinion, to each patient assuming a lifespan of 20 years and that surgeons perform a total of 255 MSs over 5 years.
Patient-Level Aggregation of Cost
This section describes the aggregation of costs, by patient, for the inpatient stay, postdischarge follow-up to 12 months, and drug use.
Hospital stay. The time in the hospital from randomization to discharge was disaggregated into theatre time, critical care unit (CCU), stay and cardiac ward stay (Table E17 ). The total length of stay comprised the time spent in surgery (measured in minutes), in the CCU (measured in hours), and in the cardiac ward (measured in days). Theatre time included the duration of reoperations where applicable (several patients had up to 2 returns to the theatre), and corresponding CCU stays were added to the CCU hours. The total stay in the hospital, calculated using theatre time, critical care, and ward stay, was compared with a direct calculation of duration using date of operation and date of discharge, to validate the breakdown of patient stay. After discharge from hospital, the majority of patients were discharged to home, but some were referred to an acute hospital or rehabilitation center (short or long term) for more care, and the costs of this additional stay were included.
Postdischarge. Data on resource use after discharge and for up to 12 months postrandomization were collected at 6-week, 6-month, and 12-month follow-up visits, with resource use divided into 3 categories: hospital admissions, tests and health care visits. A total of 28 different health care resources were used and aggregated over the follow-up period. For example, if a patient reported 1 blood test from discharge to the 6-week follow-up, 2 blood tests between the 6-week and 6-month follow-ups, and none after that, resource use was costed as £10.38 (3 3 £3.46) postdischarge.
Drugs. Drug use was matched to a corresponding unit cost using the NHS Electronic Drug tariff E5 and British National Formulary E6 to sum costs across drug type for each patient. Information on drugs administered during the primary admission was complete, with the total amount of each drug per patient checked against patient prescriptions. However, drug use postdischarge was self-reported, and it was not possible to verify or retrieve any further data on this over the follow-up period.
Health state utilities. These data were collected using EQ-5D-3L
and SF-36 questionnaires. EQ-5D-3L responses were converted to utility values using the methods described by Dolan et al. E7 and to QALYs for the trial period using the area under the curve method. SF-36 data were mapped to SF-6D utility values based on the ScHARR (School of Health and Related Research, University of Sheffield) algorithm and were converted to QALY scores as described by Brazier et al. E8 A value of 0 was assigned from date of death.
Missing Data
The patterns of missing data for resource use and utilities were tested using Pearson c 2 goodness-of-fit and Wilcoxon rank-sum tests for being missing at random and completely at random using the following variables: age, sex, treatment, and health status at baseline (EQ-5D). The baseline characteristics assessed were not statistically significantly different between the 2 groups, and multiple imputations were used for economic analysis. Patients were assigned zero cost and zero utility value from point of death.
Hospital stay. For primary admission, there were a few item nonresponses for resource use data but no censored data. Complete information was available on all respondents except for 1 participant who withdrew from the trial after operation.
Postdischarge. The frequency of missing data for resource use after discharge in the 2 groups is provided in Table E18 . Imputation models did not converge at month 12, and resource use was aggregated over time; that is, imputation was carried out for the aggregate value for each item rather than at each time period. The proportion of missing values in the aggregated utility data ranged from 11% to 25% in resource use postdischarge (Table E18 ).
Drugs. Only drugs used from the time of randomization to the 12-month follow-up were accounted for (covering 3078 uses of 118 different drugs). Various assumptions (about quantity/dose and duration of administration) were used to minimize the degree of missing information on the drugs used. For example, when dosage or frequency of dose per day was missing, the mode of use among trial participants or, if not available, the British National Formulary dosage was used. Duration of medicinal use was calculated using start and stop dates for drugs used in primary admission and follow-up. However, when start/stop dates were missing, replies to a ''yes/no'' question on use of drugs at follow-up time points informed duration. For example, if a drug was taken during the inpatient stay and at 6-week, 6-month, and 12-month follow-ups, then the drug was said to be used for the entire 12-month trial period. However, further assumptions about duration of medication were used when data were less forthcoming; for example, drugs taken only at the 12-month follow-up, without a start date or stop date specified, were assumed to have been taken according to prescription every day for an average of 3 months (based on expert consultation). Fifty-eight records had insufficient information on usage for such personalized manual imputation, necessitating predictive mean matching (conditioned on patient ID and name of drug).
Health state utilities. EQ-5D-3L and SF-6D utility data were imputed at each follow-up as presented in Table E19 , and the percentage of missing values ranged from 9% to 23%. Further breakdown of missing data for resource use and health-related quality of life questionnaires, and imputation required for each variable, is provided in Table E19 .
Imputation
Missing values were imputed conditional on sex, age, type of replacement valve used, risk classification measured using New York Heart Association functional classification and Canadian Cardiovascular Society grading of angina. To avoid loss in efficiency, missing values for resource use and utility values at different time points were replaced using multiple imputations by chained equations.
Chained predictive mean matching was used to replace missing data for resource use and quality of life variables, and a total of 20 imputed datasets were created, stratified by treatment group. The imputed resource use is summarized in Table E20 . However, although probabilistic analysis was conducted using the bootstrap method, multiple imputation was carried out only once for each iteration, with a total of 1000 iterations to adequately retain between-imputation variance. The distribution of imputed values was visually checked for comparability with the observed data.
Adjustment Method
To account for differences in baseline utility values, as well as skewness, censoring, and confounding in cost data, linear regression models were used to provide adjusted estimates of mean values. Control variables used were age, sex, valve, EQ-5D-3L baseline value, and treatment arm. The type of valve used for replacement was also controlled for, because it was used as a stratification factor in the randomization.
Incremental Cost-Effectiveness Analysis and Sensitivity Analyses
Differences in estimated costs and EQ-5D QALYs between trial arms, using raw data with imputation, were tested using a 2-sample t test with equal variances. Incremental cost-effectiveness ratios were also constructed using adjusted mean estimates of costs and QALYs using ''seemingly unrelated regression,'' to account for correlation between costs and effects at the patient level. This regression technique relies on the multivariate normality of the group-specific mean costs and QALYs and is valid where the individual costs and QALYs are skewed.
E9
Probabilistic sensitivity analysis was used to characterize the uncertainty of input parameters, and a bootstrap approach (with 1000 bootstrapped samples) was applied to estimate the precision of results. The probability that MS is cost-effective compared with FS is presented at varying willingness to pay (WTP) threshold values, using a costeffectiveness acceptability curve and incremental net monetary benefit.
Deterministic sensitivity analyses and scenario analysis were used to explore the robustness of cost-effectiveness results that adopted different methodological approaches or assumptions (Table E21) . Baseline characteristics were assessed using the c 2 and rank-sum tests, to assess whether patients included in the complete-case analysis were different from those outside the complete-case analysis.
RESULTS
The comparison of mean costs per patient up to 1 year, using raw data with imputation, shows that MS cost £1714 more than FS, although this was not statistically significant (Table E22 ). The higher costs resulted from longer surgery time, additional equipment, and longer time in critical care. EQ-5D QALYs were very slightly higher in the MS arm compared with the FS arm (difference, 0.0279), but this was not statistically significant (Table E23) , and there was no statistically significant difference in SF-6D QALYs either. Figures E2 and E3 illustrate the distribution of total costs and QALYs across the patients in the trial. Table E24 summarizes the comparison of costs and QALYs. The additional cost of gaining an additional QALY using MS rather than FS when imputed using the PMM method is £61,379, and the net monetary loss at a WTP of £20,000 is £1155.
Seemingly unrelated regression analysis of costs and QALYs, adjusted for baseline characteristics, showed that in terms of QALYS, MS was not statistically significantly different from FS. Table E25 also shows that the coefficient for cost was positive, indicating that MS was more costly than FS, and that this difference was statistically significant. Thus, MS is dominated by FS. The cost-effectiveness plane for the analysis is illustrated in Figure E4 .
The probabilistic sensitivity analysis shows that at a WTP per QALY of £20,000, there is a 3.7% likelihood that MS is cost-effective compared with FS, and that this likelihood rises to 5.1% at a WTP of £30,000/QALY ( Figure E5 ). The net monetary benefit of MS is negative across all WTP threshold values ( Figure E6 ).
Deterministic sensitivity analyses showed that MS was either dominated or had a huge ICER (Table E26 ). The one exception to this was the complete-case analysis of cost-effectiveness, which found MS to be cost-effective. The intervention cost less but also had slightly worse outcomes in this sample size, which was limited to only 90 cases. The result indicates a saving of £10,000 for a loss of 1 QALY. The sample was not representative of those with missing data and included a larger proportion of females than the sample outside the complete-case analysis cost-effectiveness sample. The sensitivity analyses conducted using probabilistic sensitivity analysis consistently found FS to be a superior intervention to MS (Table E27 ). The cost-effectiveness planes for the sensitivity analyses are illustrated in Figure E7 . 
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2132.e10 The Journal of Thoracic and Cardiovascular Surgery c December 2018
Adult: Aortic Valve Nair et al The table presents the Kaplan-Meier estimates of in-hospital endpoints. Censoring of longest time to event for some endpoints led to underestimation of means and standard errors (highlighted with asterisks). A confidence interval for median time to mobilization could not be estimated. Table E5 shows the number of pain scores obtained on each of the 10 days following surgery. The denominator used for each percentage is the number of patients known to be alive and in hospital on the given day. SE, Standard error; CI, confidence interval. *Censoring of longest time to event for some endpoints led to underestimation of means and SEs. yA CI for median time to mobilization could not be estimated.
2132.e12 The Journal of Thoracic and Cardiovascular Surgery c December 2018
Adult: Aortic Valve Nair et al The table presents the results of all analyses performed for the primary and secondary time-to-event endpoints, including unplanned, exploratory analyses of secondary endpoints. All secondary endpoint analyses, sensitivity analyses, and exploratory analyses were performed using the intent-to-treat population. All log-rank tests were stratified by valve, sex, and surgeon. All Cox models included valve, sex, and treatment as fixed effects and surgeon as a random effect. Exploratory analysis of time to all-cause death included age as a fixed effect in the Cox model. Mean imputation was used for missing EuroSCORE data at baseline (1 MS). MS, Mini-sternotomy; FS, full median sternotomy; HR, hazard ratio; CI, confidence interval; CPB, cardiopulmonary bypass. 18 (47) 12 (43) The denominator used for each percentage is the number of patients known to be alive and in the hospital on the given day. SD, Standard deviation. For patients who died, EQ-5D scores were taken to be 0 following death. Percentages presented in the table were calculated as the number of scores recorded (including the 0s) divided by the number of patients randomized to the group. The difference in mean baseline score was potentially due to the imbalance in sex; the full sternotomy group had a greater proportion of females, who reported lower quality of life on average. SD, Standard deviation. The table shows the results of complete-case analyses of questionnaire data, under a missing completely at random assumption, including only patients with at least 1 analyzable follow-up questionnaire. For each analysis, the number in parentheses is the number of patients used to fit the model. For pain and SF-36 scores, some random effects were estimated to have a variance of 0 and were excluded from the models (surgeon effect for pain and both the surgeon effect and random slope for the SF-36). The slope (time coefficient) was estimated to be negative for pain and positive for all EQ-5D and SF-36 scores. This suggests improvement over time in each score. Evidence of greater rate of improvement over time for patients in the mini-sternotomy group (statistically significant, positive interaction term) was seen for 3 SF-36 domains (role physical, vitality, and social functioning), but not for others. MS, Mini-sternotomy; FS, full sternotomy; SF-36, Short Form Health Survey; CI, confidence interval. The table presents the results from analyzing the questionnaire data using multiple imputation to handle missing observations, under a missing at random assumption. For each analysis, missing data were imputed from models that included all other variables used in the analysis, along with Canadian Cardiovascular Society grade and New York Heart Association grade as auxiliary variables. The method used was multiple imputation by chained equations with predictive mean matching. Estimates from 100 imputed datasets were combined using Rubin rules. Pain was imputed only for patients known to be alive and hospitalized, not for patients who had died or had already been discharged. Evidence of a greater rate of improvement over time for MS patients (statistically significant, positive interaction term) was seen for only 1 SF-36 domain. MS, Mini-sternotomy; FS, full sternotomy; SF-36, Short Form Health Survey; CI, confidence interval. (14) 9 (8) 29 (22) Injury/procedural 19 (11) 7 (6) 26 (17) Noncardiorespiratory infection (including wound)
7 (7) 12 (9) 19 (16) Urinary 11 (10) 8 (6) 19 (16) Surgical and medical procedures 9 (6) 7 (7) 16 (13) Nervous system 8 (8) 7 (7) 15 (15) Cardiorespiratory infection (including endocarditis, device-related infections, chest infection)
9 (9) 6 (5) 15 (14) Vascular 9 (9) 1 (1) 10 (10) Psychiatric 5 (5) 5 (5) 10 (10) Gastrointestinal, diarrhea 7 (6) 3 (3) 10 (9) Gastrointestinal, other 7 (7) 1 (1)
Blood/lymph 4 (3) 1 (1) 5 (4) The only unexpected events in the mini-sternotomy (MS) group were a bilateral pleural effusion in 1 patient, and bronchial aspiration and periarrest event in 1 patient. Both patients recovered completely. Exploratory analysis in the safety population, using logistic regression (with fixed treatment, valve, and sex effects and a random surgeon effect), did not show a statistically significant difference between MS and full sternotomy (FS) recipients in the odds of sustaining a nonfatal SAE within the first year (MS/FS odds ratio [OR], 1.559, 95% confidence interval [CI], 0.895-2.715; P ¼ .1161). An exploratory Poisson regression (with a fixed effect for treatment and a random patient effect) did show a greater rate of such SAEs for MS recipients (MS/FS rate ratio, 1.615; 95% CI, 1.070-2.437; P ¼ .0225). There were 7 cases of pericardial tamponade (4 in FS recipients and 3 in MS recipients; only 1 per patient), but logistic regression (without the random surgeon effect) did not produce a statistically significant result (MS/FS OR, 0.680; 95% CI, 0.146-3.178; P ¼ .6229). SAE, Significant adverse effect. The table shows that none of the patients who died were considered crossovers from MS to FS; however, there were 3 deaths among patients who were allocated to and received MS but who were returned to the theatre for redo FS. These were the deaths, all categorized as cardiorespiratory, occurring at 3, 26, and 933 days after surgery. FS, Full sternotomy; MS, mini-sternotomy; AS, ankylosing spondylitis. Patients who died during primary admission were the main cost driver and required substantial surgical time and cardiac care to assess whether excluding these patients would change recommendations.
Excluding additional equipment cost required
Assuming that the additional equipment required for the surgeries already exists in the trusts.
Excluding follow-up resource use To test the assumption that the cost difference between the two arms were accrued during primary admission, to allow comparison with literature that missed these costs, but still retain benefits as captured in other studies
Excluding follow-up resource use and utility data Data up to discharge had few missing values; also to assess impact of having a shorter cutoff time point for trial (as wider literature had) but provide a less biased analysis that measures benefits but not costs.
Use SF-6D utility values SF-6D values used as an alternative construction for QALYs SF-6D, Short-Form Six-Dimension; QALY, quality-adjusted life-year. 
